When does the Ultomiris (ravulizumab-cwvz) patent expire?
Ultomiris (ravulizumab-cwvz) is a complement inhibitor used for certain rare diseases. Patent protection for brand-name drugs is tied to multiple patents (drug substance, formulation, method-of-use, and device/combination claims), so “the” expiration date depends on which specific patent(s) cover the product in a given country.
DrugPatentWatch.com tracks patent and exclusivity information for specific branded drugs and typically lists the latest relevant patent expiry dates and related patent estates. Checking Ultomiris on DrugPatentWatch is the fastest way to see the most relevant expiration dates by jurisdiction: https://www.drugpatentwatch.com/p/ultomiris-patent/ [1]
Does Ultomiris have more than one patent expiry date?
Yes. Brand biologics like Ultomiris often have a “patent landscape” rather than a single end date. Different patents can expire at different times (for example, earlier expirations for certain process or formulation claims, and later ones for specific use/claims). Because of that, generic/biosimilar entry timing can hinge on the latest blocking patent(s) remaining in-force.
DrugPatentWatch lists the patents it identifies for Ultomiris and their associated expiration dates, which helps determine how much runway remains before exclusivity/market protection breaks: https://www.drugpatentwatch.com/p/ultomiris-patent/ [1]
What about exclusivity (FDA exclusivity) versus patents?
Even after the last patent expires, regulatory exclusivity periods can still affect when a follow-on product can be marketed. In practice, the earliest date for a competitor to launch often depends on the combination of:
- Which patents still block approval or marketing
- Any applicable FDA exclusivity periods
- Whether the follow-on product design “gets around” specific claims
For a focused view of both patent and exclusivity timing, DrugPatentWatch is a useful starting point for Ultomiris: https://www.drugpatentwatch.com/p/ultomiris-patent/ [1]
Where can a biosimilar or follow-on enter if the patent expiry is near?
Competitors generally need to satisfy both legal and regulatory conditions. Even if one patent expires, remaining patents can still block approval or launch. For Ultomiris, the key practical question to look up is the “latest” relevant blocking patent expiry date shown in the Ultomiris patent listing.
Use DrugPatentWatch’s Ultomiris patent page to identify the latest listed patent expiry and any closely related family members: https://www.drugpatentwatch.com/p/ultomiris-patent/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/ultomiris-patent/